upmc glp 1 coverage CMS Issues Guidance on GLP-1 Anti-Obesity Drugs UPMC Health Plan | LinkedIn

Concerns about facial volume loss, often referred to as Ozempic face, also come up

Further Reading Book: Michael Greger, Ozempic: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs (2024)

In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea

Medications can be tools, but they do not replace the basics of daily health routines

She was thinking better and clearer, and she almost made me cry because she was excited about how many changes were happening rapidly in her body